AMPK promotes tolerance to Ras pathway inhibition by activating autophagy

Area of Science:

• Oncology
• Molecular Biology
• Cellular Signaling

Background:

• Targeted Ras-Raf pathway inhibitors show promise for cancer treatment but face significant resistance issues.
• Tumor response to inhibitors includes 'addiction' (apoptosis) or 'tolerance' (reduced growth), with tolerant cells serving as a reservoir for resistance.
• Understanding mechanisms of drug tolerance is crucial for overcoming treatment resistance and preventing cancer recurrence.

Purpose of the Study:

• To investigate the role of autophagy and AMP-activated protein kinase (AMPK) in mediating tolerance to Ras-Raf pathway inhibitors.
• To determine if targeting AMPK-mediated autophagy can sensitize drug-tolerant cancer cells to targeted therapies.
• To explore therapeutic strategies combining Ras-Raf inhibitors with AMPK or autophagy blockers.

Main Methods:

• Analysis of melanoma and other cancer cell models treated with Ras-Raf pathway inhibitors.
• Investigating the activation of autophagy and its regulation by AMPK in drug-tolerant cells.
• Experimental manipulation of AMPK signaling and autophagy to assess effects on drug sensitivity.

Main Results:

• Melanomas and other cancers acquire tolerance to Ras-Raf inhibitors through AMPK-mediated activation of autophagy.
• Inhibition of AMPK-mediated autophagy sensitizes drug-tolerant melanomas to Ras-Raf inhibitors.
• Activation of AMPK signaling and autophagy allows some melanomas to tolerate Ras-Raf pathway inhibition.

Conclusions:

• AMPK-mediated autophagy is a key mechanism conferring tolerance to Ras-Raf pathway inhibitors in various cancers.
• Blocking AMPK or autophagy concurrently with Ras-Raf inhibitors may enhance tumor regression.
• Targeting this tolerance pathway offers a potential strategy to decrease cancer recurrence after targeted therapy.